C12Y 301/16001
Spleen exonuclease , i.e. 5->3 exoribonuclease
Official title: Spleen exonuclease (3.1.16.1), i.e. 5->3 exoribonuclease
C12Y301/16001 (Spleen exonuclease , i.e. 5->3 exoribonuclease) appears on 2 US grants and 7 published applications in this corpus.
Search patents in C12Y- Granted patents
- 2
- Published applications
- 7
- Assignees
- 5
- Inventors
- 17
- Latest grant
- 7 Mar 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 1 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 1 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 1 | 1 |
| 2024 | 0 | 2 |
By publication year.
Recent patents
- Methods of treating neurodegenerative conditions and compositions therefor26 Dec 2024US 2024/0424142 A1Yale University
- Genome editing systems comprising repair-modulating enzyme molecules and methods of their use25 Apr 2024US 2024/0132877 A1Editas Medicine, Inc.
- Nucleobase Editors16 Feb 2023US 2023/0051661 A1Agency for Science, Technology and Research
- Genome editing systems comprising repair-modulating enzyme molecules and methods of their use14 Nov 2019US 2019/0345490 A1Editas Medicine, Inc.
- Modulating xrn17 Feb 2013US 2013/0034543 A1Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute for Biomedical Resear
Most cited
By later US patents
No patent in this class has been cited by a later US patent yet.